Travere Therapeutics' Cline proposes $102K share sale

The notice describes a company-mandated tax-withholding sale tied to performance restricted stock units, rather than a discretionary trade by the officer.

Accepted by SEC EDGAR 05/05/2026 - 07:48 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Travere Therapeutics, Inc. (TVTX) officer Christopher Cline reported a proposed sale of 2,181 common shares, with an aggregate market value of $101,743.65, on approximately May 5, 2026.

The shares were acquired through performance restricted stock unit vesting on May 4, 2026, as compensation. The sale is mandated under the issuer’s equity incentive plans to fund tax withholding through a brokerage firm designated by the issuer; it is not a discretionary trade. Morgan Stanley Smith Barney is listed as the broker. Elizabeth E. Reed signed as attorney-in-fact for Christopher Cline.

Key Figures

Proposed shares to be sold: 2,181 common shares Aggregate market value: $101,743.65 Shares acquired through performance restricted stock unit vesting: 2,181 shares +1 more

4 metrics

Proposed shares to be sold 2,181 common shares Approximately May 5, 2026

Aggregate market value $101,743.65 Proposed sale

Shares acquired through performance restricted stock unit vesting 2,181 shares May 4, 2026

Common shares outstanding 92,992,905 shares Issuer share count listed in the securities information

Key Terms

Performance Restricted Stock Unit Vesting, sell to cover, tax withholding obligation, equity incentive plans

4 terms

Performance Restricted Stock Unit Vesting financial

"Performance Restricted Stock Unit Vesting"

sell to cover financial

"completing a "sell to cover" transaction"

Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.

tax withholding obligation financial

"fund this tax withholding obligation"

equity incentive plans financial

"under its equity incentive plans"

Equity incentive plans are company programs that pay employees, executives, or directors with company stock, stock options, or share units instead of or in addition to cash, aiming to align their interests with shareholders—like giving team members a stake in the house they help build. For investors this matters because such plans can motivate better company performance but also dilute existing ownership and increase reported compensation costs, so they affect future earnings, voting power, and share value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many TVTX shares does Christopher Cline plan to sell?

Christopher Cline reported a proposed sale of 2,181 common shares, with an aggregate market value of $101,743.65, on approximately May 5, 2026.

Why is the TVTX officer selling shares?

The sale is mandated under the issuer’s equity incentive plans to fund tax withholding associated with the settlement of vested performance restricted stock units. The notice describes it as a “sell to cover” transaction and states that it is not a discretionary trade.

What recent stock sales did Christopher Cline report for TVTX?

The reported sales were 1,014 shares for $43,206.54 on April 15, 2026; 7,239 shares for $303,522.58 and 9 shares for $369.63 on April 14, 2026; and 65 shares for $1,875.25 on April 13, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001943192
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Travere Therapeutics, Inc.
SEC File Number	001-36257
Address of Issuer	3611 Valley Centre Dr. Suite 300 San Diego CALIFORNIA 92130
Phone	888-969-7879
Name of Person for Whose Account the Securities are To Be Sold	Christopher Cline
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney 3 Edison Drive Alpharetta GA 30005	2181	101743.65	92992905	05/05/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/04/2026	Performance Restricted Stock Unit Vesting	Issuer			2181	05/04/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Christopher Cline 3611 Valley Centre Drive Suite 300 San Diego CA 92130	Common	04/15/2026	1014	43206.54
Christopher Cline 3611 Valley Centre Drive Suite 300 San Diego CA 92130	Common	04/14/2026	7239	303522.58
Christopher Cline 3611 Valley Centre Drive Suite 300 San Diego CA 92130	Common	04/14/2026	9	369.63
Christopher Cline 3611 Valley Centre Drive Suite 300 San Diego CA 92130	Common	04/13/2026	65	1875.25

144: Remarks and Signature

Remarks	Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.
Date of Notice	05/05/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Elizabeth E. Reed as attorney-in-fact for Christopher Cline
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)